{"id":52653,"date":"2023-01-06T22:02:10","date_gmt":"2023-01-06T21:02:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/"},"modified":"2023-01-06T22:02:10","modified_gmt":"2023-01-06T21:02:10","slug":"devonian-health-group-announces-executive-change-and-grant-of-stock-options","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/","title":{"rendered":"Devonian Health Group Announces Executive Change and Grant of Stock Options"},"content":{"rendered":"
\n

QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (\u201cDevonian<\/b>\u201d or the \u201cCorporation<\/b>\u201d) (TSXv: GSD; OTCQB: DVHGF<\/b>), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today executive changes within Devonian, its subsidiary Altius Healthcare inc. (\u2018\u2018Altius<\/b>\u2019\u2019) and grant of options to directors and a consultant.\n<\/p>\n

<\/a><\/p>\n

\nAs Altius enters a new phase of development, the Company has decided to retain the services of Mr. \u00c9rick Shields as Chief Commercial Officer (\u201cCCO\u201d). This appointment strengthens Altius’ management team, which is preparing to reassess its business strategy. Mrs. Sybil Dahan, who is stepping down as President of Altius, will continue to chair Devonian’s Board of Directors.\n<\/p>\n

\n\u2018\u2018I am thrilled to join Altius at this critical stage of its development and to contribute to its success\u201d said Mr. Erick Shields.\n<\/p>\n

\nAbout Erick<\/b>\n<\/p>\n

\nHolding a BAA in marketing and an Executive Masters, Mr. Erick Shields has over 30 years of experience in the pharmaceutical and medical industry in the Canadian market.\n<\/p>\n

\nHe has held various key positions in sales, marketing, market access for companies such as Abbott Laboratories, Schering Plough (now Merck), Teva Innovation Canada, and Roche where he was responsible for developing and implementing vital commercial activities. He also worked in the healthcare system at the community and hospital level and with patient associations, healthcare professionals as well as governments to facilitate access to treatments for patients. Erick also held the position of General Manager at Nutricia Canada for seven years where he was responsible for restaging the commercial business model that resulted in the largest sales growth in the company\u2019s history. More recently, Erick has been busy working as a consultant with biotech clients in Canada and the US markets.\n<\/p>\n

\nErick is recognized by his peers as a hard-working, goal driven leader with an entrepreneurial spirit who enjoys growing businesses in highly competitive environments.\n<\/p>\n

\nMr. Martin Moreau<\/b>\n<\/p>\n

\nThe Corporation also announced that Mr. Martin Moreau has resigned as Devonian\u2019s Vice-President Finance. Mr Moreau owns other business requiring his managerial competencies. Mr. Moreau will remain on Devonian\u2019s Board of Directors.\n<\/p>\n

\nGrant of options<\/b>\n<\/p>\n

\nThe Company announces that the Board of Directors has approved the granting of 100,000 stock options (the \u201cOptions<\/b>\u201d) to directors and 50,000 stock options to an employee. These options are exercisable (\u2018\u2018vested<\/b>\u2019\u2019) at $0.34 from their grant date, for a period of 10 years following the grant date.\n<\/p>\n

\nThe Company also announces that its Board of Directors has approved the granting of 1,000,000 stock options (the “Options<\/b>“) to a consultant, exercisable at a price of $0.50, for a period of ten (10) years from the date of grant. Of these 1,000,000 stock options, 300,000 are exercisable (\u2018\u2018vested<\/b>\u2019\u2019) as soon as the consulting contract is signed, while 600,000 options will be exercisable depending on the achievement of specific milestones.\n<\/p>\n

\nAbout Devonian<\/b>\n<\/p>\n

\nDevonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian\u2019s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2013 and is headquartered in Qu\u00e9bec, Canada where it owns a state-of-the art extraction facility with full traceability \u2018from the seed to the pill\u2019. Acquired in 2018, Altius Healthcare Inc., its commercialization partner, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSX Venture Exchange (TSXv:GSD).\n<\/p>\n

\nFor more information, visit www.groupedevonian.com<\/a>.\n<\/p>\n

\nForward Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements about Devonian\u2019s objectives, strategies and businesses that involve risks and uncertainties. These statements are \u201cforward-looking\u201d because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, the approval of the TSX Venture Exchange in connection with the issuance of the Units, Devonian\u2019s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian\u2019s prospectus dated April 21st<\/sup>, 2017, under the heading \u201cRisk Factors\u201d related to Devonian\u2019s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.\n<\/p>\n

\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPierre Montanaro
\n
President & CEO
\n
Devonian Health Group Inc.
\n
Telephone: (514) 909-3788
\n
Email:\u00a0pmontanaro@groupedevonian.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (\u201cDevonian\u201d or the \u201cCorporation\u201d) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today executive changes within Devonian, its subsidiary Altius Healthcare inc. (\u2018\u2018Altius\u2019\u2019) and grant of options to directors and a consultant. As Altius … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52653","6":"format-standard","7":"category-industry"},"yoast_head":"\nDevonian Health Group Announces Executive Change and Grant of Stock Options - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Devonian Health Group Announces Executive Change and Grant of Stock Options - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (\u201cDevonian\u201d or the \u201cCorporation\u201d) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today executive changes within Devonian, its subsidiary Altius Healthcare inc. (\u2018\u2018Altius\u2019\u2019) and grant of options to directors and a consultant. As Altius ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-06T21:02:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230106005239\/en\/681971\/21\/logodevonian2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Devonian Health Group Announces Executive Change and Grant of Stock Options\",\"datePublished\":\"2023-01-06T21:02:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\\\/\"},\"wordCount\":948,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005239\\\/en\\\/681971\\\/21\\\/logodevonian2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\\\/\",\"name\":\"Devonian Health Group Announces Executive Change and Grant of Stock Options - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005239\\\/en\\\/681971\\\/21\\\/logodevonian2.jpg\",\"datePublished\":\"2023-01-06T21:02:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005239\\\/en\\\/681971\\\/21\\\/logodevonian2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005239\\\/en\\\/681971\\\/21\\\/logodevonian2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Devonian Health Group Announces Executive Change and Grant of Stock Options\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Devonian Health Group Announces Executive Change and Grant of Stock Options - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/","og_locale":"en_US","og_type":"article","og_title":"Devonian Health Group Announces Executive Change and Grant of Stock Options - Pharma Trend","og_description":"QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (\u201cDevonian\u201d or the \u201cCorporation\u201d) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today executive changes within Devonian, its subsidiary Altius Healthcare inc. (\u2018\u2018Altius\u2019\u2019) and grant of options to directors and a consultant. As Altius ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-06T21:02:10+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230106005239\/en\/681971\/21\/logodevonian2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Devonian Health Group Announces Executive Change and Grant of Stock Options","datePublished":"2023-01-06T21:02:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/"},"wordCount":948,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230106005239\/en\/681971\/21\/logodevonian2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/","url":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/","name":"Devonian Health Group Announces Executive Change and Grant of Stock Options - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230106005239\/en\/681971\/21\/logodevonian2.jpg","datePublished":"2023-01-06T21:02:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230106005239\/en\/681971\/21\/logodevonian2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230106005239\/en\/681971\/21\/logodevonian2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/devonian-health-group-announces-executive-change-and-grant-of-stock-options\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Devonian Health Group Announces Executive Change and Grant of Stock Options"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52653"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52653\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}